Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Early Treatment
100%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
83%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
83%
Confidence Interval
66%
Oxaliplatin
50%
Bevacizumab
50%
Capecitabine
50%
Hazard Ratio
50%
Morphological Response
33%
Metabolic Response
33%
Colon Cancer Patients
33%
European Organizations
16%
Metabolic
16%
Predictive Value
16%
Response Evaluation Criteria in Solid Tumors (RECIST)
16%
2-deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography
16%
Monocentric
16%
First-line Chemotherapy
16%
Treatment Course
16%
Treatment Monitoring
16%
Metabolically Stable
16%
Progression-free Survival
16%
Progressive Disease
16%
Carcinoembryonic Antigen
16%
Early Response
16%
Odds Ratio
16%
Cancer Treatment
16%
Treatment Options
16%
Stable Disease
16%
Response Value
16%
Prognostic Value
16%
Log 2
16%
Plasma Tissue
16%
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Biological Marker
100%
Treatment Response
100%
Metastatic Colon Cancer
100%
Tissue Inhibitor of Metalloproteinase 1
83%
Oxaliplatin
50%
Hazard Ratio
50%
Bevacizumab
50%
Morphology
33%
Polyethylene Terephthalate
33%
Metabolism
33%
Carcinoembryonic Antigen
16%
Progressive Disease
16%
Odds Ratio
16%
Urokinase Receptor
16%
Fluorodeoxyglucose F 18
16%
Progression Free Survival
16%
Response Evaluation Criteria in Solid Tumors
16%
First-Line Chemotherapy
16%
Cancer Treatment
16%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colon Cancer
100%
Biological Marker
100%
Tissue Inhibitor of Metalloproteinase 1
83%
Capecitabine
50%
Bevacizumab
50%
Oxaliplatin
50%
Polyethylene Terephthalate
33%
Solid Malignant Neoplasm
16%
Progression Free Survival
16%
Carcinoembryonic Antigen
16%
Diseases
16%
Malignant Neoplasm
16%
Fluorodeoxyglucose F 18
16%
First-Line Chemotherapy
16%
Urokinase Receptor
16%
Agricultural and Biological Sciences
Positron-Emission Tomography
100%
Computed Tomography
100%
Colon
100%
Metalloprotease Inhibitor
83%
Confidence Interval
66%
Polyethylene Terephthalate
33%
Metabolism
33%
Blood Plasma
33%
Urokinase Receptor
16%
Odds Ratio
16%
Carcinoembryonic Antigen
16%
Immunology and Microbiology
Colon
100%
Positron Emission Tomography-Computed Tomography
100%
Morphology
33%
Metabolism
33%
Blood Plasma
33%
Urokinase Receptor
16%
Progression Free Survival
16%
Carcinoembryonic Antigen
16%